Compare ClearPoint Neuro Inc (CLPT) vs ServiceNow Inc (NOW) Price & Performance

ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.

Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.

ServiceNow (NOW) trades at $104.85, down 2.66% on the day, amid a generally bullish technical and fundamental backdrop. The stock exhibits strong revenue growth, with 2025 revenue reaching $13.28B and a robust net income margin of 12.59%. Analyst sentiment is overwhelmingly positive, with an 85.51% buy rating and a consensus price target of $137.96, suggesting significant upside potential. Recent news highlights the company's positioning as an 'AI control tower,' with strong performance in May.

The outlook for NOW is favorable, driven by AI adoption and consistent earnings beats, though high valuation multiples (P/E of 66.23) pose a risk if growth slows. Key investment opportunities include expanding profit margins and market share in enterprise software, while risks involve competitive pressures and execution challenges in a high-interest-rate environment.